Anemia is a disease that is often associated with heart failure (HF) and renal insufficiency (RI). This unfavorable triad of conditions has been called Cardio-Renal-Anemia Syndrome (CRS). The association of HF, RI, and anemia is poorly reported in multicenter clinical trials, so the pathophysiologic mechanisms and treatment options need to be better defined. When CRS patients develop anemia, a "perfect storm" often occurs: HF and RI cause anemia which will worsen the first two conditions. Anemia appears to be the result of complex interactions between cardiac performance, bone marrow homeostasis, renal dysfunction, and various drug side effects. However, neurohormonal and inflammatory activities play a key role in the beginning and progression of the disease. As a consequence, endogenous erythropoietin activity dysfunction with inadequate production and tissue resistance occurs. Despite the advances of therapy in the neurohormonal activation blockade, mortality and hospitalization in HF still remain unacceptably high, suggesting that specific comorbidity treatments could have a significant positive prognostic impact. Anemia should be recognized as one of the novel targets in HF treatment. © 2011 Springer Science+Business Media, LLC.

Palazzuoli, A., Antonelli, G., Nuti, R. (2011). Anemia in Cardio-Renal Syndrome: clinical impact and pathophysiologic mechanisms. HEART FAILURE REVIEWS, 16(6), 603-607 [10.1007/s10741-011-9230-x].

Anemia in Cardio-Renal Syndrome: clinical impact and pathophysiologic mechanisms

Nuti R.
2011-01-01

Abstract

Anemia is a disease that is often associated with heart failure (HF) and renal insufficiency (RI). This unfavorable triad of conditions has been called Cardio-Renal-Anemia Syndrome (CRS). The association of HF, RI, and anemia is poorly reported in multicenter clinical trials, so the pathophysiologic mechanisms and treatment options need to be better defined. When CRS patients develop anemia, a "perfect storm" often occurs: HF and RI cause anemia which will worsen the first two conditions. Anemia appears to be the result of complex interactions between cardiac performance, bone marrow homeostasis, renal dysfunction, and various drug side effects. However, neurohormonal and inflammatory activities play a key role in the beginning and progression of the disease. As a consequence, endogenous erythropoietin activity dysfunction with inadequate production and tissue resistance occurs. Despite the advances of therapy in the neurohormonal activation blockade, mortality and hospitalization in HF still remain unacceptably high, suggesting that specific comorbidity treatments could have a significant positive prognostic impact. Anemia should be recognized as one of the novel targets in HF treatment. © 2011 Springer Science+Business Media, LLC.
2011
Palazzuoli, A., Antonelli, G., Nuti, R. (2011). Anemia in Cardio-Renal Syndrome: clinical impact and pathophysiologic mechanisms. HEART FAILURE REVIEWS, 16(6), 603-607 [10.1007/s10741-011-9230-x].
File in questo prodotto:
File Dimensione Formato  
palazzuoli 2011(heart fail rev).pdf

accesso aperto

Licenza: DRM non definito
Dimensione 177.8 kB
Formato Adobe PDF
177.8 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/395651
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo